{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-192292","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2022-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.411210+00:00","generated_at":"2026-06-24T15:57:18.293746+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Revolution Medicines appoints Lorence Kim to Board, replacing Neil Exter","bullets":["Dr. Kim appointed Class I director effective July 12, 2022, filling vacancy from Exter's resignation.","Determined independent; qualifies as audit committee financial expert; served on Audit Committee.","Venture Partner at Third Rock Ventures, former CFO of Moderna, and ex-Managing Director at Goldman Sachs.","Received initial option for 36,800 shares and 10,500 RSUs under Non-Employee Director Compensation Program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-192292","json":"https://secwatch.observer/filing/0001193125-22-192292.json","markdown":"https://secwatch.observer/filing/0001193125-22-192292.md","text":"https://secwatch.observer/filing/0001193125-22-192292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/0001193125-22-192292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/d335098d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T15:57:18.293746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8448270bf5","claim":"Neil Exter resigned as Director at Revolution Medicines, Inc..","evidence_excerpt":"Dr. Kim was appointed to fill the vacancy on the Board created by the resignation of Neil Exter, who resigned from the Board, effective July 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/0001193125-22-192292-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ce31c7181c","claim":"Lorence Kim was appointed as Class I Director at Revolution Medicines, Inc..","evidence_excerpt":"On July 9, 2022, the Board of Directors (“Board”) of Revolution Medicines, Inc. (the “Company”) appointed Lorence Kim, M.D., as a member of the Board, effective July 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/0001193125-22-192292-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}